TD Cowen Maintains Buy on Ascendis Pharma, Raises Price Target to $341

Benzinga · 3d ago
TD Cowen analyst Yaron Werber maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and raises the price target from $325 to $341.